Deal focus: Pfizer’s strategic financing for CellCentric’s inobrodib

Pfizer, one of the world’s biggest pharmaceutical companies, has provided CellCentric strategic financing for its lead candidate, inobrodib. As part of the deal, vice president for Pfizer’s Tumour Biology, Astrid Ruefli-Brasse, will join CellCentric’s scientific advisory board and Sriram Krishnaswami, vice president and development head for multiple myeloma, will serve as an advisor.